Cornel Medical Limited is a leading technology development and licensing business specialising in microdialysis and patient monitoring. Cornel draws on the experience and knowledge of a pool of scientists, engineers, manufacturing, marketing and regulatory specialist to create technology-enabled business opportunities.
Cornel Medical Board
Chairman & CEO
Mike Sundler, Chairman and CEO, is a highly experienced senior executive with more than 25 years in international marketing, sales, and senior general management experience in the medical device industry. He was Senior VP at Advanced Bionics, (at one time the neuro-modulation division of Boston Scientific) from 2004 to 2017 and during this period he achieved significant annual growth rates in both direct and indirect markets across different countries and continents.
A serial bio-tech entrepreneur with extensive experience of start-up companies, particularity in the life sciences sector, both private and listed. Director at Excelya, a contract research organisation (CRO) specialist in Central and South-Eastern Europe providing clinical trial services to the global drug development industry. With O’Connell, co-founded Probe Scientific Limited, Somnus Scientific Limited and Cornel Medical Limited.
MIBiol, CBiol (London), PhD (London)
While studying for his PhD at the Institute of Neurology, London, he began using the then novel technique of brain microdialysis. As Principal Biochemist at the National Hospital for Neurology and Neurosurgery, London from 1991 to 1995, Mark pioneered the application of clinical microdialysis. In 1993 he began using intravenous microdialysis for drug monitoring in patients, publishing this ‘proof-of-principle’ work in the British Journal of Clinical Pharmacology. As Senior Clinical Scientist at Addenbrooke’s Hospital, University of Cambridge until 2005, his knowledge and expertise helped establish Cambridge as a leading centre in the field of microdialysis. Mark is an international speaker and author of over 50 scientific and medical papers.